Globe Life (NYSE: GL) Shows Strong Performance and Positive Analyst Outlook

Font: Financial Modeling Prep  • Jul 10, 2026

• Globe Life (NYSE: GL) demonstrates robust market performance, trading near its 52-week high and significantly outperforming its industry, sector, and the S&P 500.
• Analysts maintain a positive outlook, with Jefferies increasing its price target for Globe Life, reflecting confidence in the company's future value.
• The company exhibits strong financial health, driven by a 12% growth in operating EPS, significant health sales increases, and a substantial capital return strategy, projecting considerable excess cash flow.

Globe Life (NYSE: GL) is an insurance holding company with a market capitalization of approximately $13.89 billion. The company provides various life and supplemental health insurance products. Its stock currently trades at $178.86, which is near its 52-week high of $182.32, indicating strong market performance and investor interest.

On July 10, 2026, Jefferies increased its price target on Globe Life to $166.00 from a previous target of $147.00. As highlighted by TheFly, this new target was announced when the stock was already trading higher at $178.86. This adjustment reflects a positive analyst outlook on the company's future value.

This confidence is supported by the stock's recent performance. According to Zacks Investment Research, shares of Globe Life have gained 48.7% over the past year. This growth surpasses its industry, its sector, and the S&P 500 composite. The stock has also outperformed peers like Aflac Incorporated and Unum Group.

The company's financial strength is a key driver of this performance. It reports a 12% growth in operating Earnings Per Share (EPS), which measures profit per share of stock. This growth is fueled by higher premium income, disciplined underwriting (the process of evaluating risk), and increased income from investments.

Globe Life also shows strong sales momentum, with health sales increasing by 58%. The company has a robust capital return strategy, having returned $225.00 million to shareholders. It anticipates generating between $650.00 million and $700.00 million in excess cash flow in 2026, signaling continued financial health.